MAP3K5 and ischemia: The A1R agonist 2-Chloro-N6-cyclopentyladenosine (CCPA) enhances ischemia-reperfusion (IR) damage, intracellular steatosis, and oxidative species (OS) production, thereby further increasing lipid/OS-dependent apoptosis signal regulating kinase 1 (ASK1)-c-jun N-terminal kinase (JNK) stimulation [147].